The pan-KRAS inhibitors (e.g., RMC-6236, YL-17231, JAB-23425, JAB-23400) mainly targeted to Son of Sevenless 1 (SOS1) proteins, which inhibited their capacity to catalyze the binding of KRAS to GTP, as well as the transition of KRAS from inactive to active state, inactivating KRAS, and consequently inhibiting tumor development [116, 117]. The gene discussed is KRAS; the disease is neoplasm.